Table 1.
Summary of sputum miRNA information in lung cancer.
| Reference | Year | Country | Cases | Controls | Comparative Test | Discovery Phase |
|---|---|---|---|---|---|---|
| [19] | 2010 | USA | 64 | 58 | Histopathology | Yes |
| [18] | 2010 | USA | 67 | 55 | Histopathology | Yes |
| [16] | 2010 | USA | 23 | 17 | Cytology | Yes |
| [21] | 2012 | Canada | 24 | 6 | Histopathology | Yes |
| [15] | 2013 | USA | 39 | 42 | Histopathology | Yes |
| [4] | 2014 | USA | 64 | 73 | Histopathology | Yes |
| [17] | 2014 | USA | 35 | 40 | Histopathology | Yes |
| [22] | 2015 | Canada | 21 | 10 | Histopathology | Yes |
| [20] | 2015 | USA | 56 | 73 | Histopathology | Yes |
| Reference | Methods | miRNA Assay | miRNA Profiling | Sensitivity (%) | Specificity (%) | |
| [19] | Literature and training set (36 cases and 36 controls) | RT-PCR and qRT-PCR | miRNA-21 ,200b, 375, 486 | 70.3 | 80 | |
| [18] | Literature and training set (48 cases and 48 controls) | RT-PCR | miRNA-205, 210, 708 | 72 | 95 | |
| [16] | Literature | RT-PCR | miRNA-21, 155 | 69.6 | 100 | |
| [21] | Literature and training set (4 cases and 4 controls) | RT-PCR and qRT-PCR | miRNA-21, 143, 155, 210, 372 | 100 | 83.3 | |
| [15] | Literature | qRT-PCR | miRNA-31, 210 | 61.5 | 90.5 | |
| [4] | Literature and training set (66 cases and 68 controls) | qRT-PCR | miRNA-31, 210 | 64.1 | 89.2 | |
| [17] | Literature | qRT-PCR | miRNA-31, 210 | 65.7 | 85 | |
| [22] | Literature | RT-PCR and qRT-PCR | miRNA-21, 143, 155, 210, 372 | 67.8 | 90 | |
| [20] | Literature | qRT-PCR | miRNA-21, 31, 210 | 83.7 | 87.5 |